vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and OXFORD INDUSTRIES INC (OXM). Click either name above to swap in a different company.
OXFORD INDUSTRIES INC is the larger business by last-quarter revenue ($307.3M vs $180.9M, roughly 1.7× AVANOS MEDICAL, INC.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -20.7%, a 20.0% gap on every dollar of revenue. On growth, AVANOS MEDICAL, INC. posted the faster year-over-year revenue change (0.7% vs -0.2%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $-47.9M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -3.0%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Oxford Industries, Inc. is a publicly traded clothing company in the United States that specializes in high-end clothing and apparel. The company carries many major labels, including Tommy Bahama, Lilly Pulitzer, Johnny Was and Southern Tide.
AVNS vs OXM — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $307.3M |
| Net Profit | $-1.3M | $-63.7M |
| Gross Margin | 47.5% | 60.3% |
| Operating Margin | 1.4% | -27.7% |
| Net Margin | -0.7% | -20.7% |
| Revenue YoY | 0.7% | -0.2% |
| Net Profit YoY | 99.7% | -1517.6% |
| EPS (diluted) | $-0.02 | $-4.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $307.3M | ||
| Q3 25 | $177.8M | $403.1M | ||
| Q2 25 | $175.0M | $392.9M | ||
| Q1 25 | $167.5M | — | ||
| Q4 24 | $179.6M | $308.0M | ||
| Q3 24 | $170.4M | $419.9M | ||
| Q2 24 | $171.7M | $398.2M | ||
| Q1 24 | $166.1M | $404.4M |
| Q4 25 | $-1.3M | $-63.7M | ||
| Q3 25 | $-1.4M | $16.7M | ||
| Q2 25 | $-76.8M | $26.2M | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $-397.3M | $-3.9M | ||
| Q3 24 | $4.3M | $40.6M | ||
| Q2 24 | $1.8M | $38.4M | ||
| Q1 24 | $-900.0K | $-60.1M |
| Q4 25 | 47.5% | 60.3% | ||
| Q3 25 | 48.4% | 61.4% | ||
| Q2 25 | 52.6% | 64.2% | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | 63.1% | ||
| Q3 24 | 54.5% | 63.1% | ||
| Q2 24 | 55.7% | 64.9% | ||
| Q1 24 | 57.1% | 60.9% |
| Q4 25 | 1.4% | -27.7% | ||
| Q3 25 | 0.1% | 6.3% | ||
| Q2 25 | -42.6% | 9.2% | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | -233.0% | -2.0% | ||
| Q3 24 | 7.0% | 12.5% | ||
| Q2 24 | 3.7% | 13.2% | ||
| Q1 24 | 2.4% | -20.1% |
| Q4 25 | -0.7% | -20.7% | ||
| Q3 25 | -0.8% | 4.1% | ||
| Q2 25 | -43.9% | 6.7% | ||
| Q1 25 | 3.9% | — | ||
| Q4 24 | -221.2% | -1.3% | ||
| Q3 24 | 2.5% | 9.7% | ||
| Q2 24 | 1.0% | 9.6% | ||
| Q1 24 | -0.5% | -14.9% |
| Q4 25 | $-0.02 | $-4.28 | ||
| Q3 25 | $-0.03 | $1.12 | ||
| Q2 25 | $-1.66 | $1.70 | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $-8.64 | $-0.25 | ||
| Q3 24 | $0.09 | $2.57 | ||
| Q2 24 | $0.04 | $2.42 | ||
| Q1 24 | $-0.02 | $-3.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $8.0M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $528.0M |
| Total Assets | $1.1B | $1.3B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $8.0M | ||
| Q3 25 | $70.5M | $6.9M | ||
| Q2 25 | $90.3M | $8.2M | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | $7.0M | ||
| Q3 24 | $89.0M | $18.4M | ||
| Q2 24 | $92.2M | $7.7M | ||
| Q1 24 | $75.8M | $7.6M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | $29.0M |
| Q4 25 | $778.2M | $528.0M | ||
| Q3 25 | $778.0M | $597.1M | ||
| Q2 25 | $776.3M | $592.4M | ||
| Q1 25 | $839.4M | — | ||
| Q4 24 | $828.5M | $612.2M | ||
| Q3 24 | $1.2B | $621.6M | ||
| Q2 24 | $1.2B | $592.9M | ||
| Q1 24 | $1.2B | $560.9M |
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.0B | $1.3B | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | $1.2B | ||
| Q3 24 | $1.7B | $1.2B | ||
| Q2 24 | $1.7B | $1.2B | ||
| Q1 24 | $1.7B | $1.1B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | 0.05× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $-9.1M |
| Free Cash FlowOCF − Capex | $21.3M | $-47.9M |
| FCF MarginFCF / Revenue | 11.8% | -15.6% |
| Capex IntensityCapex / Revenue | 3.8% | 12.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $-79.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $-9.1M | ||
| Q3 25 | $14.0M | $83.5M | ||
| Q2 25 | $6.8M | $-3.9M | ||
| Q1 25 | $25.7M | — | ||
| Q4 24 | $57.9M | $-18.2M | ||
| Q3 24 | $23.0M | $88.8M | ||
| Q2 24 | $27.8M | $32.9M | ||
| Q1 24 | $-8.0M | $74.9M |
| Q4 25 | $21.3M | $-47.9M | ||
| Q3 25 | $7.0M | $52.3M | ||
| Q2 25 | $-4.2M | $-27.4M | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | $-56.9M | ||
| Q3 24 | $20.0M | $47.2M | ||
| Q2 24 | $21.9M | $21.0M | ||
| Q1 24 | $-12.1M | $55.3M |
| Q4 25 | 11.8% | -15.6% | ||
| Q3 25 | 3.9% | 13.0% | ||
| Q2 25 | -2.4% | -7.0% | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | -18.5% | ||
| Q3 24 | 11.7% | 11.2% | ||
| Q2 24 | 12.8% | 5.3% | ||
| Q1 24 | -7.3% | 13.7% |
| Q4 25 | 3.8% | 12.6% | ||
| Q3 25 | 3.9% | 7.7% | ||
| Q2 25 | 6.3% | 6.0% | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | 12.6% | ||
| Q3 24 | 1.8% | 9.9% | ||
| Q2 24 | 3.4% | 3.0% | ||
| Q1 24 | 2.5% | 4.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 5.00× | ||
| Q2 25 | — | -0.15× | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | 2.19× | ||
| Q2 24 | 15.44× | 0.86× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
OXM
| Sales Channel Retail | $162.9M | 53% |
| Sales Channel Wholesale | $61.3M | 20% |
| Johnny Was | $45.4M | 15% |
| Sales Channel Food And Beverage | $29.3M | 10% |
| Other Foreign Countries | $9.0M | 3% |
